Novo Nordisk A/S (NYSE:NVO) was downgraded by equities researchers at UBS Group from a “buy” rating to a “neutral” rating in a report issued on Monday, November 18th, The Fly reports.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
A number of other research analysts also recently weighed in on the stock. Pareto Securities upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Monday, August 5th. Barclays upgraded shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a report on Monday, November 18th. Citigroup upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 17th. Bank of America raised their price target on shares of Novo Nordisk A/S from $355.00 to $400.00 and gave the stock a “neutral” rating in a research report on Friday, September 13th. Finally, ValuEngine upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $159.65.
Novo Nordisk A/S stock traded up $1.44 during midday trading on Monday, reaching $55.90. The stock had a trading volume of 74,976 shares, compared to its average volume of 1,550,166. The firm’s fifty day simple moving average is $54.37 and its two-hundred day simple moving average is $51.12. Novo Nordisk A/S has a twelve month low of $43.60 and a twelve month high of $58.01. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market cap of $128.96 billion, a price-to-earnings ratio of 22.21, a PEG ratio of 2.18 and a beta of 0.61.
Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. Novo Nordisk A/S had a net margin of 32.44% and a return on equity of 75.48%. The firm had revenue of $4.51 billion during the quarter, compared to analyst estimates of $4.55 billion. As a group, sell-side analysts predict that Novo Nordisk A/S will post 2.45 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of the company. Advisors Preferred LLC acquired a new stake in Novo Nordisk A/S during the second quarter worth about $26,000. Winthrop Partners WNY LLC acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $28,000. Prime Capital Investment Advisors LLC acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $28,000. Valeo Financial Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 510.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 629 shares of the company’s stock valued at $32,000 after purchasing an additional 526 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC boosted its stake in shares of Novo Nordisk A/S by 75.6% in the 2nd quarter. Wealthcare Advisory Partners LLC now owns 864 shares of the company’s stock valued at $44,000 after purchasing an additional 372 shares in the last quarter. 7.30% of the stock is currently owned by institutional investors.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Featured Story: Inverted Yield Curve